For the week, the S&P 500 was up 3%, while the Dow Jones Industrial Average increased 2.2% and the Nasdaq shot up 6.1%.
ETFG Equity Exposure Report - Regeneron Pharmaceuticals Inc. (REGN) saw its stock surge this week, on news that it is developing promising COVID-19 treatments. The ETFs weighted most heavily with Regeneron stock are the iShares Genomics Immunology and Healthcare ETF (IDNA), the Loncar Cancer Immunotherapy ETF (CNCR), and the iShares Nasdaq Biotechnology ETF (IBB).
ETFG Quant Movers - Those ETFs who have had the largest weekly change in their respective, overall ETFG Quant ratings.
ETFG Quant Winners: This week, we are highlighting the ETFs that saw the largest movement in the fundamental component of our ETFG Quant model.
The ETFs with the biggest increases in their ETFG Fundamental Quant scores this week were the Global X SuperIncome Preferred ETF (SPFF), the ETRACS Linked to the Wells Fargo Business Development Company Index ETN (BDCS), the ETRACS Alerian MLP Index ETN (AMU), the iPath S&P MLP ETN (IMLP), and the Shares US Preferred Stock ETF (PFF).
ETFG Quant Losers: This week’s ETFs charting the steepest declines in their ETFG Fundamental Quant scores were the Invesco Preferred ETF (PGX), VanEck Vectors Gaming ETF (BJK), the SPDR Wells Fargo Preferred Stock ETF (PSK), the ELEMENTS SPECTRUM ETN (EEH), and the SPDR S&P Biotech ETF (XBI).
ETFG Weekly Select List - The five most highly rated ETFs per Sector, Geographic Region and Strategy as ranked by the ETFG Quant model.
As COVID-19 developments continue to drive the market, we focus on the 5 ETFs in the Healthcare sector with the highest ratings from our ETFG Quant model. They are the SPDR S&P Biotech ETF (XBI), the Invesco Dynamic Biotechnology & Genome ETF (PBE), the Principal Healthcare Innovators Index (BTEC), the VanEck Vectors Biotech ETF (BBH), and the First Trust NYSE Arca Biotechnology Index Fund (FBT).
Thanks for reading ETF Global Perspectives!
ETFG 21 Day Free Trial: https://www.etfg.com/signup/quick
Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. ETF Global LLC (“ETFG”) and its affiliates and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively ETFG Parties) do not guarantee the accuracy, completeness, adequacy or timeliness of any information, including ratings and rankings and are not responsible for errors and omissions or for the results obtained from the use of such information and ETFG Parties shall have no liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of such information. ETFG PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall ETFG Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the information contained in this document even if advised of the possibility of such damages.
ETFG ratings and rankings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities or to make any investment decisions. ETFG ratings and rankings should not be relied on when making any investment or other business decision. ETFG’s opinions and analyses do not address the suitability of any security. ETFG does not act as a fiduciary or an investment advisor. While ETFG has obtained information from sources they believe to be reliable, ETFG does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income.